Past list view

NYC Bio and the Center for Biotechnology invite you to the fourth session of the “Nuts and Bolts of Biotechnology Entrepreneurship” series to be held on December 9th 2009.

The session " Crossing the Valley of Death: guides to translational, pre-seed and seed funding " features:

Jahanara Ali, Senior Vice President, New York City Investment Fund

Brian Cohen, Director, New York Angels

Franklin Madison, Technology Program Director, Industrial & Technology Assistance Corporation of New York.

Dear Members,

NYC Bio and the Center for Biotechnology invite you to the second session of the “Nuts and Bolts of Biotechnology Entrepreneurship” series to be held on October 7th 2009.

The session “Intellectual Property and Technology Licensing" features panelists:

• Kathleen Denis, Ph.D., Associate Vice President, Technology Transfer, Rockefeller University;
• Abram Goldfinger, Executive Director, Industrial Liasion/Technology Transfer, NYU; and
• Daryn A. Grossman, Partner and Co-Chair of the Technology, Media and Communications practice group, Proskauer Rose LLP.

Venue:
Stony Brook Manhattan
401 Park Avenue South (between 27th and 28th Streets), 2nd Floor
New York, NY 10016

Time: 6:30-8:00 PM on October 7th, 2009.

There is a fee of $10 for this session. All payments should be made through PayPal when you RSVP on the meetup website: http://biotech.meetup.com/40.

Note: If you are arriving before 7:00 pm, you can use the 401 Park Avenue South entrance (between 27th and 28th Streets) to come to the Main Hall on the second floor. After 7:00 pm, you need to use the 110 East 28th Street entrance.

We look forward to seeing you there.

NYC Bio
The Center for Biotechnology

Attend Part 2 of an interactive workshop for the development of a Thought Leadership Strategy & Plan that you can use now to gain recognition for your best assets -- your own thought leadership or the thought leadership of others in your organization. Mobilize your own expertise or the talent already under your roof and in your network.

Facilitator for the workshop: Doris Gilman, President of "Be Seen. Be Heard. Inc."

By July 24, please fill out and submit to Doris a plan for your thought leadership project, using the template provided at the link below.

In the July 28 workshop, a number of plans (selected in advance) will be presented and discussed. All plans will receive complimentary offline follow-up from Doris.

Template

Panel Discussion: Venture Capital Investment in Early Stage Life Science Company
-This event is proudly hosted and co-sponsored by Baker Botts, LLP1
and co-sponsored by the New York City Bioscience Initiative2.

Lead panelists: Chau Khuong (OrbiMed), Will Shen (J&J) and Nick Wachtel (Lux Capital)
Venue: 44th Floor, 30 Rockefeller Plaza, New York, NY 10112
Time: 6:00pm – Thursday, November 6th

Topics to be covered:
· What are the investment strategies of life science venture capital firms?
· How does the current credit crunch affect investment in early stage life science companies?
· How can biotech entrepreneurs make deals with VC?
· Who should early stage life science companies talk to, corporate or VC firms?

About the lead panelists:
Chau Q. Khuong, Private Equity Principal, OrbiMed LLC. Mr. Khuong joined OrbiMed, which is the world's largest healthcare-dedicated investment firm with over $6 billion in assets under management, in 2003 to focus on biotechnology and medical device investments into both private equity and small capitalization public companies. Mr. Khuong holds a B.S. degree in Molecular, Cellular, and Developmental Biology (Concentration in Biotechnology) and a Master's in Public Health (Concentration in Infectious Disease), both from Yale University. He was actively involved in OrbiMed investments in Arius Research (acquired by Roche, 2008), Peninsula Pharmaceuticals (acquired by JNJ, 2005), Cerexa (acquired by Forest, 2007), Adiana (acquired by Cytyc, 2007), Biodel (NASDAQ: BIOD), and Emphasys Medical. Mr. Khuong currently serves on the Board of Directors at Cerapedics and is an Observer on the Board of Directors at Biolex, Glaukos, and Pieris AG.

Will Shen, Johnson & Johnson. Mr. Shen is a member of the biopharmaceutical investment team at Johnson & Johnson Development Corporation, the venture capital arm of J&J. He currently serves as a board observer of Optherion and also played a significant role in JJDC's investment in Catalyst Biosciences. Will received his MBA from the Wharton School of the University of Pennsylvania, focusing on Finance and Healthcare Management. At Wharton, Will worked closely with Penn's Center for Technology Transfer on the commercialization of a polymer-based nanoparticle technology. Will earned his PhD in Chemical Engineering from Stanford University. He completed his BS in Chemistry from the University of Florida.

Nick Wachtel, Lux Capital. Mr. Wachtel is an associate with Lux Capital, based in the firm's New York office. He joined Lux in early 2005 and focuses on early-stage investments in nanotechnology, biotechnology, and alternative energy. Nick has worked with Lux portfolio companies including Genocea, Magen, and Tempo Pharmaceuticals. Prior to joining Lux, he worked at Delta Group, a New York private equity firm. Nick received his B.B.A in Finance from Emory University's Goizueta Business School. Nick is one of the founders of Young Wall Street, a non-profit organization dedicated to improving the lives of New York City's youths and adolescents. Nick has been a featured speaker at a number of conferences and an invited lecturer on the topics of nanotechnology and venture capital at various universities including Cornell.

1Baker Botts L.L.P., dating from 1840, is a leading international law firm with offices in Austin, Beijing, Dallas, Dubai, Hong Kong, Houston, London, Moscow, New York, Palo Alto, Riyadh and Washington. With more than 800 lawyers, Baker Botts provides a full range of legal services to international, national and regional clients.

2New York City Bioscience Initiative is a private public partnership with New York City Economic Development Corporation, New York City Investment Fund, and Partnership for New York City, the city’s research institutions and members of the investment community

On NYC Bio September 18th Meetup,
James Chinitz, CEO of Population Diagnostics will present about
Population Diagnostics and personalized medicine.

The evening will be devoted to the emerging field of personalized medicine. After the presentation, James Chinitz will engage the audience in a deeper discussion of the general field.

The September 18th Meetup is sponsored by Morrison & Foerster, LLP.